Search

Your search keyword '"Jensen E"' showing total 167 results

Search Constraints

Start Over You searched for: Author "Jensen E" Remove constraint Author: "Jensen E" Database ScienceDirect Remove constraint Database: ScienceDirect
167 results on '"Jensen E"'

Search Results

4. Timing of HPV16-E6 antibody seroconversion before OPSCC: findings from the HPVC3 consortium

12. 1210P Neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy and adjuvant pembro or pbo for early stage NSCLC: Subgroup analyses of the phase III KEYNOTE-671 study

24. Measurement of the single-spin asymmetry [formula omitted] in quasi-elastic 3He↑(e,e′n) scattering at 0.4

25. Measurement of double-polarization asymmetries in the quasi-elastic [formula omitted] process

26. Technical supplement to “Polarization transfer observables in elastic electron-proton scattering at [formula omitted] and [formula omitted]”

28. 973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC

31. 726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775)

36. 43O Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia

37. 1O KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC)

38. LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%

41. LBA4 - Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro

44. 901P - Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045

Catalog

Books, media, physical & digital resources